Gagandeep Kaur Khara, NP

Gagandeep Khara practices at Sequoia Vista Care in Visalia, California.

Gagandeep Khara's NPI, 1407416480, was assigned on June 20, 2019. Gagandeep Khara holds California license 95011690.

Gagandeep Khara's primary practice is Sequoia Vista Care, at 3710 West Tulare Avenue, Visalia, CA 93277 in Tulare County. The practice phone is (559) 732-2244.

Gagandeep Khara's primary practice is Sequoia Vista Care in Visalia, California. Gagandeep Khara is also affiliated with Saint Agnes Medical Center. The medical group on file is Community Health Partners. Dmand AI also links Gagandeep Khara to 5 more medical groups and 1 therapy and rehab clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Gagandeep Khara practices, 3 sites in all. Vendor and product names are available with a free account.

Nurse practitioner is Gagandeep Khara's primary specialty in the NPI Registry, under taxonomy code 363L00000X. Gagandeep Khara is licensed in California.

Dmand AI lists bladder disease, chronic diabetes, chronic kidney disease, chronic obstructive pulmonary disease (COPD), depression, enlarged prostate, high cholesterol and mobility impairment among the conditions Gagandeep Khara treats.

CMS data shows 14,650 Medicare services from Gagandeep Khara across 18 procedure codes in 2024, for 397 Medicare patients. Medicare paid $89,409 for them.

CMS counts 397 Medicare patients who saw Gagandeep Khara in 2024. The largest group is 65 to 74, with 159 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 55% are also on Medicaid. Their average risk score is 1.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Gagandeep Khara's median patient age at 62, with 49% women.

In 2024, Gagandeep Khara wrote 1,446 Medicare Part D claims for 604 patients. 86% of them were for generic drugs. CMS names the drug for 1,211 of them, across 21 drugs with 11 or more claims each, at $116,407 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Gagandeep Khara for performance year 2024, reported as part of a group. Gagandeep Khara accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 49 general payments to Gagandeep Khara from 13 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 80% of the total. Sumitomo Pharma America, Inc. paid the most, $311.